CANADA LIFE ASSURANCE Co Has $37.38 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

CANADA LIFE ASSURANCE Co raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,836 shares of the life sciences company’s stock after buying an additional 13,563 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Illumina were worth $37,382,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ILMN. XTX Topco Ltd acquired a new stake in shares of Illumina during the 3rd quarter valued at $226,000. M&T Bank Corp raised its position in Illumina by 3.4% in the third quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company’s stock valued at $7,091,000 after purchasing an additional 1,769 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Illumina during the third quarter valued at about $772,000. Tidal Investments LLC boosted its stake in shares of Illumina by 38.0% during the third quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company’s stock valued at $580,000 after purchasing an additional 1,226 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. grew its holdings in shares of Illumina by 66.8% during the third quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company’s stock worth $1,582,000 after purchasing an additional 4,797 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ILMN. Royal Bank of Canada dropped their price objective on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a report on Tuesday, April 8th. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Morgan Stanley reduced their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. Finally, Barclays reduced their price target on Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average price target of $138.70.

Illumina Stock Down 3.2 %

Illumina stock opened at $71.21 on Friday. The company has a market capitalization of $11.27 billion, a PE ratio of -9.27, a PEG ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The firm’s fifty day moving average is $84.61 and its 200 day moving average is $120.40. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.